Sprout AI Inc. announced that it has been selected as the cultivation technology of choice for the purpose of cultivating controlled substances for JT Medical LLC based in Pennsylvania, USA. This order forms part of a larger TheraCann project with an arm’s length party and confirms the Company’s ability to meet and exceed DEA Licensing requirements to ensure repeatability and the highest quality of plant-derived medicines. The total number of units to be delivered by the Company over the next 12 months will be based on JT Medical securing their cultivation request for domestic and/or international research and development projects. On Sept. 2, 2021, the DEA proposed a substantial increase in the amount of marijuana and psilocybin that can be legally produced for research. The DEA stated these are necessary steps toward potential Food and Drug Administration (FDA) approval of new drug products. TheraCann will provide further updates and place orders simultaneously to the company as the project expands. Assurance that subsequent orders will be required or fulfilled is unsecured as all orders will be subject to the project site readiness, availability of inventory, volatility in the supply chain of critical components for the Units and other risk factors inherent in the agricultural business. Under the terms of the Order, an initial payment of 50% is required at the time of the Order to commence assembly. The remaining 50% of the Order is due at the time of shipping. All payments are non-refundable. Shipment of the Order is expected in the fourth quarter of 2021.